Aurobindo Pharma’s wholly owned subsidiary, CuraTeQ Biologics, has received a Notice of Compliance (NOC) from Health Canada for Bevqolva™, a bevacizumab biosimilar. The drug, which inhibits angiogenesis to treat various cancers, meets rigorous safety, efficacy, and quality standards. This approval follows the product’s successful 2025 launch in the UK and underscores the company’s expanding global footprint in the biosimilar market, with additional applications currently undergoing regulatory review.
Advancing Oncology Treatment
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has reached a significant milestone with the approval of Bevqolva™ by Health Canada. This biosimilar is designed as a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), effectively inhibiting the formation of new blood vessels that support tumor growth. The therapy is indicated for the treatment of multiple cancers, including colorectal and lung cancer.
Strategic Global Expansion
The approval marks another step in the commercial rollout of this therapy, which was already authorized and launched in the United Kingdom in 2025. Bevqolva™ will be available in 100 mg and 400 mg formulations to suit diverse patient needs. Beyond this achievement, the company continues to bolster its pipeline, with two additional biosimilar candidates currently awaiting regulatory assessment by Health Canada, while the CHMP of the European Medicines Agency is also reviewing the product for broader market access.
Source: BSE
